NZ502660A - Pyrimidyl- or (oxazolyl- or thiazolyl-)oxy substituted carboxylic acid derivatives useful as mixed ETA/ETB endothelin-receptor antagonists - Google Patents

Pyrimidyl- or (oxazolyl- or thiazolyl-)oxy substituted carboxylic acid derivatives useful as mixed ETA/ETB endothelin-receptor antagonists

Info

Publication number
NZ502660A
NZ502660A NZ502660A NZ50266098A NZ502660A NZ 502660 A NZ502660 A NZ 502660A NZ 502660 A NZ502660 A NZ 502660A NZ 50266098 A NZ50266098 A NZ 50266098A NZ 502660 A NZ502660 A NZ 502660A
Authority
NZ
New Zealand
Prior art keywords
phenyl
cooh
ch2ch2ch2
alkyl
ome
Prior art date
Application number
NZ502660A
Other languages
English (en)
Inventor
Manfred Raschack
Liliane Unger
Stefan Hergenroder
Wilhelm Amberg
Rolf Jansen
Dagmar Klinge
Hartmut Riechers
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19738578A external-priority patent/DE19738578A1/de
Priority claimed from DE1998111915 external-priority patent/DE19811915A1/de
Application filed by Basf Ag filed Critical Basf Ag
Publication of NZ502660A publication Critical patent/NZ502660A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ502660A 1997-09-04 1998-08-24 Pyrimidyl- or (oxazolyl- or thiazolyl-)oxy substituted carboxylic acid derivatives useful as mixed ETA/ETB endothelin-receptor antagonists NZ502660A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19738578A DE19738578A1 (de) 1997-09-04 1997-09-04 Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
DE1998111915 DE19811915A1 (de) 1998-03-18 1998-03-18 Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
PCT/EP1998/005354 WO1999011629A1 (de) 1997-09-04 1998-08-24 Neue carbonsäurederivate, ihre herstellung und verwendung als gemischte eta/etb-endothelin-rezeptorantagonisten

Publications (1)

Publication Number Publication Date
NZ502660A true NZ502660A (en) 2002-02-01

Family

ID=26039663

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ502660A NZ502660A (en) 1997-09-04 1998-08-24 Pyrimidyl- or (oxazolyl- or thiazolyl-)oxy substituted carboxylic acid derivatives useful as mixed ETA/ETB endothelin-receptor antagonists

Country Status (21)

Country Link
EP (1) EP1009741A1 (tr)
JP (1) JP2001514254A (tr)
KR (1) KR20010023615A (tr)
CN (1) CN1269792A (tr)
AR (1) AR017052A1 (tr)
AU (1) AU748610B2 (tr)
BG (1) BG104222A (tr)
BR (1) BR9811631A (tr)
CA (1) CA2302350A1 (tr)
CO (1) CO4970738A1 (tr)
HR (1) HRP980484A2 (tr)
HU (1) HUP0004935A3 (tr)
ID (1) ID25620A (tr)
IL (1) IL134276A0 (tr)
NO (1) NO20001077L (tr)
NZ (1) NZ502660A (tr)
PL (1) PL338954A1 (tr)
SK (1) SK1522000A3 (tr)
TR (1) TR200000602T2 (tr)
TW (1) TW546295B (tr)
WO (1) WO1999011629A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19924892A1 (de) * 1999-06-01 2000-12-07 Basf Ag Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
CN101454283A (zh) * 2006-05-29 2009-06-10 尼科克斯公司 作为内皮素受体拮抗剂的硝化的杂环化合物
MX2010009607A (es) 2008-03-05 2010-09-30 Boehringer Ingelheim Int Derivados de piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su preparacion.
JP5531097B2 (ja) * 2009-07-10 2014-06-25 カディラ・ヘルスケア・リミテッド アンブリセンタンを調製するための改善された方法およびその新規な中間体
AP2012006390A0 (en) 2010-02-19 2012-08-31 Boehringer Ingelheim Int Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
AR087577A1 (es) 2011-08-17 2014-04-03 Boehringer Ingelheim Int Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparacion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
EP0885217A4 (en) * 1996-02-01 1999-04-21 Smithkline Beecham Corp ENDOTHELIN RECEPTOR ANTAGONISTS
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten

Also Published As

Publication number Publication date
EP1009741A1 (de) 2000-06-21
AU9533398A (en) 1999-03-22
BG104222A (en) 2001-02-28
HUP0004935A2 (hu) 2001-10-28
HRP980484A2 (en) 1999-06-30
SK1522000A3 (en) 2000-08-14
NO20001077D0 (no) 2000-03-02
CO4970738A1 (es) 2000-11-07
PL338954A1 (en) 2000-12-04
CN1269792A (zh) 2000-10-11
TW546295B (en) 2003-08-11
WO1999011629A1 (de) 1999-03-11
IL134276A0 (en) 2001-04-30
AU748610B2 (en) 2002-06-06
HUP0004935A3 (en) 2001-12-28
JP2001514254A (ja) 2001-09-11
AR017052A1 (es) 2001-08-22
KR20010023615A (ko) 2001-03-26
BR9811631A (pt) 2000-09-26
TR200000602T2 (tr) 2000-12-21
NO20001077L (no) 2000-03-02
ID25620A (id) 2000-10-19
CA2302350A1 (en) 1999-03-11

Similar Documents

Publication Publication Date Title
AU763976B2 (en) Th2 differentiation inhibitors
AU731579B2 (en) Novel alpha-hydroxy acid derivatives, their preparation and use
TW201011040A (en) Ring-fused morpholine derivative having pi3k-inhibiting activity
AU711293B2 (en) Novel carboxylic acid derivatives, their preparation and use
ZA200200392B (en) Isoxazoline derivatives and herbicides containing the same as the active ingredient.
SK25999A3 (en) Azinyloxy-and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed eta/etb endothelin receptor antagonists
EA010628B1 (ru) 5-фенилпиримидины, способ их получения, содержащие их средства и их применение
AU748610B2 (en) Novel carboxylic acid derivatives, their production and their their use as mixed ETa/ETb endothelin-receptor antagonists
AU740351B2 (en) Heterocyclic carboxylic acid derivatives, their preparation ans use as endothelin receptor antagonists
SK176299A3 (en) New 'beta'-amino and 'beta'-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor antagonists
AU765345B2 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists
WO1999042453A1 (de) 5-substituierte pyrimidin-2-yloxy-carbonsäurederivate, deren herstellung und deren verwendung als endothelin-antagonisten
CZ326298A3 (cs) Deriváty kyseliny karoxylové a jejich použití
MXPA01005635A (en) New b-amide and b-sulfonamide carboxylic acid derivatives, their preparation and their use as endothelin receptor antagonists
SK11752000A3 (sk) Nesymetricky substituované deriváty karboxylových kyselín, spôsob ich prípravy a ich použitie ako zmesových antagonistov eta/etb receptora
AU6561500A (en) Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists
NZ504289A (en) Heterocyclically substituted alpha-hydroxycarboxylic acid derivatives, method for producing the same and their use as endothelin receptor antagonists
MXPA00007417A (en) Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta
WO2002064573A1 (de) Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
CA2340167A1 (en) New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists
HRP970503A2 (en) Novel carboxylic acid derivatives, their production and their use as mixed eta/etb receptor antagonists
MXPA00006463A (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists

Legal Events

Date Code Title Description
PSEA Patent sealed
ASS Change of ownership

Owner name: ABBOTT GMBH AND CO. KG, DE

Free format text: OLD OWNER(S): BASF AKTIENGESELLSCHAFT